OBR Daily Commentary

forumImage

IMpower131: Final Overall Survival Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

(IASLC 2019) Sept 10, 2019 - Patients with Stage IV squamous non-small cell lung cancer enrolled in clinical trial to test the immunotherapy atezolizumab and chemotherapy against chemotherapy alone experienced a longer survival rate, among a subgroup of patients with high PD-LI. The data for the Impower131 Trial was presented today by Dr. F. Cappuzzo, from Azienda Unità Sanitaria Locale della Romagna, Ravenna/Italy at the IASLC 2019 World Conference on Lung Cancer, hosted by the International Association for the Study of Lung Cancer.

Read Article arrow

donsharpe (Posted: September 16, 2019)

quotesThank you for catching that Dr. Xu. We consulted with Dr. West and he agrees he made a mistake on that one. We have made the correction now. Thanks!quotes

Add Comment 3 Comment
forumImage

Alphabet-Backed Flatiron Health Is Being Acquired By Roche

(CNBC) Feb 15, 2018 - Swiss pharma giant Roche is acquiring Flatiron Health, which has an electronic medical record used by physicians treating cancer, then analyzes the information to come up with better treatments.

Read Article arrow

William McGivney (Posted: February 22, 2018)

quotesI do not what they call it today, but remember the Buzzwords, “Rapid Heath Learning” (RHL) from about 7 years ago. That term came and went fairly quickly; as such terms are wont to do. There were many terms prior to RHL and I would expect that there are many Buzzword terms still to come. Getting away from semantical genre to the developing realization from Roche that has sequentially purchased Genentech, Foundation Medicine, other diagnostic entities, and now Flatiron (Flatiron purchased Altos Solutions EMR in 2014), the development and utilization of drugs/biologics will continue the march to the application of: 1. Real World Evidence (RWE or aka data) to expand indications 2. to support drugs/biologics in combination 3. to enhance hypothesis generation to identify new biomarkers for drugs and biologics (old and novel) 4. to develop the innovative drugs and biologics that target newly identified biomarkers There is more but the strategic path is clear. Questions lurk such as: 1. When will the data source, quality, diversity, quantities, specificity, accuracy, recency etc. be sufficient to support the applications listed above? 2. Is the selected EHR sufficiently operable across systems for centers and larger practices to be happy to participate and provide data? 3. How and will the real owners of data (i.e., patients, providers) participate and share in the next $1.9 billion windfall? 4. What are the missing pieces or upgrades that are still needed? I do not know but it will be great to watch as “evidence-based medicine”, “outcomes-based decision-making”, “rapid health learning”, etc. actually comes to fruition in the competitive private sector!quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...